NDC-11 (Package) | NDC-9 (Product) | Generic Name (Descending) | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00703-5233-93 | 00703-5233 | Daunorubicin Hydrochloride | Daunorubicin Hydrochloride | 5.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | April 1, 2004 | June 30, 2016 | In Use |
61958-0301-01 | 61958-0301 | Daunorubicin | DaunoXome | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | April 8, 1996 | July 1, 2011 | No Longer Used | |
10885-0001-01 | 10885-0001 | Daunorubicin | DaunoXome | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Feb. 13, 2012 | April 16, 2016 | No Longer Used | |
00003-0524-11 | 00003-0524 | Dasatinib | Sprycel | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | June 27, 2006 | In Use | |
00003-0527-11 | 00003-0527 | Dasatinib | Sprycel | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | June 27, 2006 | In Use | |
00003-0528-11 | 00003-0528 | Dasatinib | Sprycel | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | June 27, 2006 | In Use | |
00003-0855-22 | 00003-0855 | Dasatinib | Sprycel | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Oct. 28, 2010 | In Use | |
00003-0857-22 | 00003-0857 | Dasatinib | Sprycel | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Oct. 28, 2010 | In Use | |
54868-5759-00 | 54868-5759 | Dasatinib | Sprycel | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb. 12, 2007 | In Use | |
60505-3628-06 | 60505-3628 | Dasatinib | Dasatinib | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 3, 2024 | In Use | |
60505-3629-06 | 60505-3629 | Dasatinib | Dasatinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 3, 2024 | In Use | |
60505-3630-06 | 60505-3630 | Dasatinib | Dasatinib | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 3, 2024 | In Use | |
60505-3631-03 | 60505-3631 | Dasatinib | Dasatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 3, 2024 | In Use | |
60505-3816-03 | 60505-3816 | Dasatinib | Dasatinib | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 3, 2024 | In Use | |
60505-3817-03 | 60505-3817 | Dasatinib | Dasatinib | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 3, 2024 | In Use | |
66993-0233-60 | 66993-0233 | Dasatinib | Dasatinib | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 3, 2024 | In Use | |
66993-0234-60 | 66993-0234 | Dasatinib | Dasatinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 3, 2024 | In Use | |
66993-0235-60 | 66993-0235 | Dasatinib | Dasatinib | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 3, 2024 | In Use | |
66993-0236-30 | 66993-0236 | Dasatinib | Dasatinib | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 3, 2024 | In Use | |
66993-0237-30 | 66993-0237 | Dasatinib | Dasatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 3, 2024 | In Use | |
66993-0238-30 | 66993-0238 | Dasatinib | Dasatinib | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 3, 2024 | In Use | |
83858-0101-60 | 83858-0101 | Dasatinib | PHYRAGO | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 1, 2024 | In Use | |
83858-0102-60 | 83858-0102 | Dasatinib | PHYRAGO | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 1, 2024 | In Use | |
83858-0103-60 | 83858-0103 | Dasatinib | PHYRAGO | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 1, 2024 | In Use | |
83858-0104-30 | 83858-0104 | Dasatinib | PHYRAGO | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 1, 2024 | In Use | |
83858-0105-30 | 83858-0105 | Dasatinib | PHYRAGO | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 1, 2024 | In Use | |
83858-0106-30 | 83858-0106 | Dasatinib | PHYRAGO | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 1, 2024 | In Use | |
00003-0852-11 | 00003-0852 | Dasatinib | Sprycel | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | June 3, 2009 | Jan. 26, 2011 | In Use |
00003-0852-22 | 00003-0852 | Dasatinib | Sprycel | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 30, 2008 | In Use | |
50419-0395-01 | 50419-0395 | Darolutamide | Nubeqa | 300.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 31, 2019 | In Use | |
50419-0395-72 | 50419-0395 | Darolutamide | Nubeqa | 300.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | March 3, 2021 | In Use | |
54868-5428-00 | 54868-5428 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Sept. 13, 2006 | June 30, 2013 | No Longer Used | |||
54868-5429-00 | 54868-5429 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | March 20, 2008 | June 30, 2013 | No Longer Used | |||
54868-5867-00 | 54868-5867 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | March 20, 2008 | June 30, 2013 | No Longer Used | |||
55513-0006-01 | 55513-0006 | Darbepoetin alfa | Aranesp | 200.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sept. 11, 2006 | In Use | ||
55513-0010-01 | 55513-0010 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Oct. 1, 2001 | March 31, 2009 | No Longer Used | |||
55513-0010-04 | 55513-0010 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Oct. 1, 2001 | March 31, 2009 | No Longer Used | |||
55513-0011-01 | 55513-0011 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Oct. 1, 2001 | Nov. 30, 2008 | No Longer Used | |||
55513-0011-04 | 55513-0011 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Oct. 1, 2001 | Nov. 30, 2008 | No Longer Used | |||
55513-0012-01 | 55513-0012 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Oct. 1, 2001 | Dec. 31, 2008 | No Longer Used | |||
55513-0012-04 | 55513-0012 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Oct. 1, 2001 | Dec. 31, 2008 | No Longer Used | |||
55513-0013-01 | 55513-0013 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Oct. 1, 2001 | April 30, 2009 | No Longer Used | |||
55513-0013-04 | 55513-0013 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Oct. 1, 2001 | April 30, 2009 | No Longer Used | |||
55513-0028-01 | 55513-0028 | Darbepoetin alfa | Aranesp | 200.0 ug/.4mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug. 14, 2006 | In Use | ||
55513-0032-01 | 55513-0032 | Darbepoetin alfa | Aranesp | 500.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | June 7, 2006 | In Use | ||
55513-0037-01 | 55513-0037 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Feb. 18, 2011 | Nov. 30, 2008 | No Longer Used | |||
55513-0037-04 | 55513-0037 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Feb. 18, 2011 | Nov. 30, 2008 | No Longer Used | |||
55513-0048-01 | 55513-0048 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Feb. 10, 2004 | Feb. 28, 2009 | No Longer Used | |||
55513-0053-01 | 55513-0053 | Darbepoetin alfa | Aranesp | 150.0 ug/.75mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sept. 11, 2006 | In Use | ||
55513-0053-04 | 55513-0053 | Darbepoetin alfa | Aranesp | 150.0 ug/.75mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sept. 11, 2006 | In Use |
Found 10,000 results in 15 milliseconds — Export these results